The U.S. Food & Drug Administration declined to approve two China-tested cancer treatments on Monday, saying one of the companies – Hutchmed Ltd. – needs to test its drug for the U.S. population in a diverse multi-regional trial.

Efforts by Novartis to defend its blockbuster cancer drug Afinitor against competitors got a boost from European regulators, who approved it for use on certain types of advanced gastrointestinal and lung neuroendocrine tumors.